Manufacturer of soft contact lenses CooperVision has launched its Biofinity XR contact lens brand, an extension to its popular Biofinity (comfilcon A) silicone hydrogel technology.
The Biofinity XR lens is reportedly the first lens that combines high oxygen permeability with all-day comfort characteristics, allowing greater levels of oxygen to freely flow through the lens.
According to the company, Biofinity XR lens allows practitioners to confidently fit a greater number of monthly replacement lens patients, including those with significant hyperopia and myopia.
Biofinity XR is the only extended range monthly contact lens brand with Aquaform technology.
This technology optimises the relationship between oxygen and water, creating a softer, more flexible lens material, helping keep them clearer and whiter with less irritation.
The Aquaform technology makes the lens material breathable, with more oxygen reaching the eyes, helping keep them clearer and whiter with less irritation.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also ensures that the lenses are naturally and uniformly wettable for smoothness and comfort, and maintains softness and flexibility for more gentle wear from the first day to the last, the company said.
CooperVision global professional and clinical affairs senior vice-president Dr Juan Carlos Aragon said: “The availability of Biofinity XR gives eye care practitioners another reason to make it a monthly lens of choice, whether transitioning Proclear wearers, upgrading from a competitive lens, or introducing a broader span of spectacle wearers to soft lenses.”
Biofinity XR lenses are currently available in powers from +8.50 to +15.00 (0.50 steps) and -12.50 to -20.00 (0.50 steps). The current Biofinity line continues to be available in +8.00 to -12.00 powers.
According to GlobalData estimates, the contact lenses market in the US was valued at $2.6bn in 2012 and is expected to grow at a CAGR of 3.5% to reach $3.31bn by 2019.